聚焦万亿级电子信息产业创新生态构建，11月13日，"投资盖碗茶"电子信息产业创新生态构建交流会在双流区屏芯智能制造总部基地举行。 ▲活动现场 成都的人才与产业链优势成为焦点。陈眩杰介绍智能采血机器人时，道出选择成都的深层原因：团队核心成员多来自本地高校，成都人才密度高，为企业提 供创新动力。同时，成都完善的生物医药产业链和医疗资源，吸引各类高端医疗器械科技企业落地发展。他坦言，"目前，我们正同华西医院、成都市第三 人民医院开展研发合作，等产品上市后，成都也是我们市场推广的重点城市。" ▲活动现场 现场，电子信息产业领域的创新型中小企业、科研院所、学（协）会及投资机构等代表齐聚，就项目布局、产品推广、场景应用、融资对接等进行深度交流 合作，为成都电子信息产业链"补空白、强弱项、国产自主"积蓄势能。 "我们冲着融资来的。"凯瑞医疗科技有限公司总经理助理陈眩杰开门见山，落座后他便与邻座投资人交流并交换联系方式，而这正是活动力求营造的交流对 接效果。会场内，数十家代表如同老友聚会，话题从宏观政策聊到技术细节，轻松氛围让合作的齿轮加速转动。 据悉，"投资盖碗茶"政企见面会，是全市投资促进系统深入实施"立园满园"行动、常 ...

（原标题：机器人、低空持续火热，一星机器人种子轮融资数亿元｜投融资周报） 一句话趋势：具身智能持续火热，低空经济备受关注，芯片与半导体赛道热度不减。 过去一周披露的投融资案例显示，科技与制造行业依旧是资本关注重点，低空经济赛道备受青睐。微分智飞（杭州）科技有限公司连续完成两亿 元Pre-A轮和Pre-A+轮融资，其中，Pre-A轮融资由东方富海、洪泰基金领投，雅瑞资本跟投；Pre-A+轮由华映资本领投，深创投、尚颀资本、长 石资本跟投。 消费服务 医疗健康领域，生物医药依然表现稳健，大额融资方面，北京华龛生物科技有限公司宣布完成数亿元B+轮融资，本轮融资汇聚多家头部投资机 构，包括北京市医药健康产业投资基金、北京市新材料产业投资基金、工融顺禧基金、京国瑞基金、国新基金、远至资本、招银国际资本、重庆 向新力基金、国康基金、中关村资本等。 消费服务领域，专注中式汉堡的麒麟燚餐饮管理（成都）有限责任公司宣布完成1860万元A轮融资，由四川智胜资本投资。 21创投不完全统计，9月15日—9月21日，报告日期内国内一级市场发生融资事件24起。其中，有21笔融资披露了融资金额和币种信息，总规模约 合人民币30.496亿元 ...

Core Insights - Minauth has launched the "Grassroots Medical AI Diagnosis Project" driven by policy and market demand, utilizing "AI + microfluidics + blockchain" technology to create an intelligent sampling and testing closed loop for county-level medical communities, addressing the "impossible triangle" of grassroots healthcare [1][2] - The company's core product, the "Magic Lab Intelligent Diagnostic System," received its Class II medical device registration in May 2025, marking its entry into clinical application [1][4] Industry Context - The global healthcare market is nearing $10 trillion, with the U.S. healthcare expenditure surpassing $4.9 trillion in 2023, of which approximately 75% is allocated to service delivery. The shortage of healthcare resources is becoming increasingly severe, with 16.7% of U.S. hospitals anticipating critical staffing shortages [2] - In China, 1.07 million grassroots medical institutions lack testing capabilities, with 80% of tests relying on higher-level hospitals, leading to inefficiencies and long wait times for patients [2] Technological Advancements - The application of AI in medical equipment has evolved from single-function assistance to a comprehensive intelligent ecosystem covering the entire lifecycle of research, production, clinical use, and regulation. From 2018 to 2024, 379 domestic AI medical devices have been approved in China, indicating a shift from "assisted diagnosis" to "full disease management" [3] - The "Magic Lab" system integrates an automated blood collection robot and multifunctional analyzer, achieving a fully automated process from blood collection to report generation, significantly reducing the time required for diagnostics [5][6] Operational Efficiency - The "Magic Lab" system can perform nearly 100 tests in about 15 minutes, compared to traditional methods that take 1-2 days. This system allows for painless blood collection in just 3 minutes, enhancing patient experience and accessibility [5][6] - The operational costs for a typical township health center using "Magic Lab" are projected to be 13.6% lower than traditional external testing methods over three years, with significant savings in labor costs due to reduced reliance on specialized personnel [7] Market Potential - The demand for integrated testing solutions in grassroots medical institutions is substantial, with a potential market exceeding 500 billion yuan in China. The government is promoting the expansion of quality medical resources to improve regional healthcare equity [9][10] - Minauth has initiated the "Village Health" project to provide systematic training for grassroots healthcare workers and optimize product adaptability, aiming to enhance the stability and compatibility of its systems in complex environments [10] Clinical Validation and Future Prospects - The "Magic Lab" system has been clinically validated in nearly 20 top-tier hospitals, serving over 200,000 patients and securing 45 patents, establishing a strong technological moat with no direct competitors anticipated in the next 3-5 years [11] - The company is set to launch a 100 million yuan Series A financing round, focusing on research and market expansion, positioning itself as a potential unicorn in the AI healthcare sector [12]

Group 1: Financing and Investment - ShunJing Pharmaceutical has completed a 300 million RMB Series A financing round, led by multiple investment firms including Songhe Fund and Dacheng Fund [1] - The funds will primarily be used to accelerate the Phase II clinical trials of SGC001, a novel antibody drug for acute myocardial infarction, and other core pipeline IND applications and clinical research [1] - Horizon Robotics has announced a successful 100 million USD Series A financing round, attracting numerous domestic and international investors [2] Group 2: Product Development and Innovation - ShunJing Pharmaceutical focuses on developing first-in-class (FIC) and best-in-class (BIC) drugs, with SGC001 being the fastest in development, having received IND approval from both the FDA and the National Medical Products Administration [1] - The company aims to enhance its strategic layout in the biopharmaceutical industry, aligning with China's 14th Five-Year Plan for biopharmaceutical development [1] - Horizon Robotics has built a complete product system covering chips, algorithms, and software to meet the diverse needs of intelligent robots across various sectors [3] Group 3: Market Expansion and Ecosystem - ShunJing Pharmaceutical's funding is expected to deepen its strategic layout and enhance its long-term operational development [1] - Horizon Robotics is expanding its developer ecosystem, empowering over 200 small and medium-sized creators and incubating nearly 100 new types of intelligent robots [5] - The company has established partnerships with over 200 universities to cultivate talent in the field of intelligent robotics [6] Group 4: Industry Trends and Future Outlook - The financing activities reflect a growing interest in the biopharmaceutical and intelligent robotics sectors, indicating a robust investment climate [2][4] - Companies are increasingly focusing on integrating innovative technologies and expanding their product offerings to capture larger market shares [2][5] - The advancements in intelligent robotics and biopharmaceuticals are expected to contribute significantly to the overall growth of the respective industries in the coming years [1][3]

Core Insights - In May, Tianhu Technology recorded 21 investment and financing events related to technology innovation and entrepreneurship in Chengdu, indicating a vibrant investment landscape in the region [1][3]. Group 1: Investment Events - Chengdu Hailong Aerospace Technology Co., Ltd. completed angel round financing, focusing on the development of star sensors and magnetic moment devices [2][10]. - Chengdu Zhongke Xingchen Information Technology Co., Ltd. secured equity financing, specializing in satellite mobile communication terminals [2][11]. - Chengdu Xinglu Aerospace Technology Co., Ltd. completed equity financing, engaged in satellite technology integration [2][12]. - Sichuan Jushen Humanoid Robot Technology Co., Ltd. raised tens of millions in angel round financing, focusing on humanoid robots [2][13]. - Chengdu Jiuzhang Zhifang Technology Co., Ltd. completed equity financing, providing technology promotion services [2][14]. - Chengdu Annu Intelligent Technology Co., Ltd. raised tens of millions in seed round financing, focusing on humanoid robot applications [2][15]. - Chengdu Chengfa Kenen Power Engineering Co., Ltd. completed A round financing, specializing in industrial power equipment [4]. - Chengdu Chuangyi Micro-Nano Technology Co., Ltd. completed angel round financing, focusing on specialized instrument manufacturing [6]. - Sichuan Blue Ocean Intelligent Equipment Manufacturing Co., Ltd. completed A round financing, specializing in intelligent equipment for underground engineering [7]. - Chengdu Jingzhan Electronic Technology Co., Ltd. completed A round financing, focusing on power semiconductor chip design [8]. - Sichuan Jinlong Microelectronics Technology Co., Ltd. completed A round financing, specializing in MEMS silicon oscillators [9]. - Chengdu Weikang Biotechnology Co., Ltd. completed equity financing, focusing on biotechnology research [17]. - Chengdu Kerry Medical Technology Co., Ltd. completed tens of millions in Pre-A round financing, focusing on intelligent blood collection robots [18]. - Sichuan Tiannuo Juneng New Energy Development Co., Ltd. completed equity financing, focusing on lithium-silicon anode materials [19]. - Chengdu Hangxin Aviation Equipment Technology Co., Ltd. completed equity financing, specializing in aviation parts manufacturing [21]. - Chengdu Xinghan Aerospace Technology Co., Ltd. completed equity financing, focusing on rocket control systems [22]. Group 2: Market Trends - The majority of financing events were in the seed and angel round stages, indicating a focus on early-stage investments [3]. - The digital economy and electronic information sectors were the hottest investment areas in Chengdu, with nearly 30% of projects related to the digital economy and about 25% related to electronic information [3].